[CAS NO. 1037210-93-7] Saridegib
PRODUCTS SPECIFICATIONS [1037210-93-7]
DESCRIPTION [1037210-93-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 504.77 |
| Molecular Formula | C29H48N2O3S |
| SMILES | CC1=C(C[C@@]2([H])[C@@]3([H])CC[C@@]4([H])[C@]2(C)CC[C@@H](NS(C)(=O)=O)C4)[C@@]3([H])CC[C@@]([C@@H]5C)(C1)O[C@@]6([H])[C@@]5([H])NC[C@@H](C)C6 |
Summary
Saridegib is a potent and specific inhibitor of Smoothened (Smo) , a key signaling transmembrane protein in the Hedgehog (Hh) pathway.
IC50 & Target
Smo [1] .
In Vivo
Evidence from a genetically engineered mouse model of pancreatic cancer demonstrates that Saridegib (IPI-926) can deplete tumor-associated stromal tissue and increase intratumoral mean vessel density. These changes result in enhanced delivery of concurrently administered systemic agents, leading to a decreased tumor burden and prolonged survival in this mouse model [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01310816 | Infinity Pharmaceuticals, Inc. |
Conventional Chondrosarcoma
|
February 2011 | Phase 2 |
| NCT01609179 | Infinity Pharmaceuticals, Inc. |
Basal Cell Carcinoma|Chondrosarcoma
|
March 2012 | Not Applicable |
| NCT02762084 | PellePharm, Inc. |
Basal Cell Nevus Syndrome
|
June 6, 2016 | Phase 2 |
| NCT02828111 | PellePharm, Inc. |
Basal Cell Carcinomas
|
November 11, 2016 | Phase 2 |
| NCT01383538 | Andrew Ko|Infinity Pharmaceuticals, Inc.|University of California, San Francisco |
Pancreatic Cancer|Adenocarcinoma|Pancreatic Neoplasms
|
August 23, 2011 | Phase 1 |
| NCT04155190 | PellePharm, Inc. |
Recurrent Basal Cell Carcinoma
|
December 20, 2019 | Phase 2 |
| NCT03703310 | PellePharm, Inc. |
Basal Cell Nevus Syndrome
|
February 19, 2019 | Phase 3 |
| NCT01371617 | Infinity Pharmaceuticals, Inc. |
Primary Myelofibrosis|Fibrosis, Bone Marrow
|
October 2011 | Phase 2 |
| NCT04308395 | PellePharm, Inc. |
Basal Cell Nevus Syndrome
|
June 3, 2020 | Phase 3 |
| NCT01130142 | Infinity Pharmaceuticals, Inc. |
Metastatic Pancreatic Cancer
|
April 2010 | Phase 1|Phase 2 |
| NCT01255800 | University of Colorado, Denver |
Recurrent Head and Neck Cancer
|
April 2011 | Phase 1 |
| NCT00761696 | Infinity Pharmaceuticals, Inc. |
Neoplasms
|
September 2008 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Synonyms